Literature DB >> 11344349

Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma.

I Vachier1, C Chavis, M Majori, M Farce, J Bousquet, P Godard, P Chanez.   

Abstract

BACKGROUND: Human blood polymorphonuclear cells, which biosynthesize eicosanoids from the 5-lipoxygenase (5-LO) pathway, are likely to be involved in asthma, in which glucocorticoids represent the first line of therapy. Their effects on leukotriene release after a short course of treatment, which have been reported in several studies, are controversial.
OBJECTIVE: We sought to investigate whether long-term oral glucocorticoids inhibit lipid mediators from the 5-LO pathway.
METHODS: Twelve normal control subjects, 29 asthmatic subjects, and 50 glucocorticoid-dependent asthmatic subjects were included in the study. Polymorphonuclear cells were studied for endogenous and transcellular metabolism of eicosanoids.
RESULTS: Total leukotriene B(4) production was significantly lower in cells from glucocorticoid-dependent asthmatic subjects (mean +/- SD, 177 +/- 26 ng/10(7) cells) than in control subjects (406 +/- 27), untreated asthmatic subjects (421 +/- 34), and asthmatic subjects treated with inhaled glucocorticoids (290 +/- 56). When incubated with arachidonic acid, these polymorphonuclear cells released very low amounts of 5(S)- and 12(S)-hydroxy-eicosatetraenoic acid (HETE), whereas endogenous 15(S)-HETE was found in substantial amounts. The transformation of exogenous 15(S)-HETE into 5(S),15(S)-diHETE and lipoxins was significantly more important in untreated asthmatic subjects than in control subjects and glucocorticoid-dependent asthmatic subjects.
CONCLUSION: This study showed that long-term oral corticotherapy affects the 5-LO activity and leads to a decrease production of all metabolites in contrast to short-term or inhaled glucocorticoids. This study also questions the site of action of glucocorticoids in regulating the availability of arachidonic acid and potential eicosanoid regulation, as previously held in phospholipase A2 studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344349     DOI: 10.1067/mai.2001.113868

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

1.  Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients.

Authors:  Nina Kim; Thomas H Thatcher; Patricia J Sime; Richard P Phipps
Journal:  JCI Insight       Date:  2017-02-09

2.  Corticosteroid suppression of lipoxin A4 and leukotriene B4 from alveolar macrophages in severe asthma.

Authors:  Pankaj K Bhavsar; Bruce D Levy; Mark J Hew; Michael A Pfeffer; Shamsah Kazani; Elliot Israel; Kian Fan Chung
Journal:  Respir Res       Date:  2010-06-07

Review 3.  All along the watchtower: group 2 innate lymphoid cells in allergic responses.

Authors:  Madelene W Dahlgren; Ari B Molofsky
Journal:  Curr Opin Immunol       Date:  2018-06-01       Impact factor: 7.486

4.  Pilot application of lipoxin A4 analog and lipoxin A4 receptor agonist in asthmatic children with acute episodes.

Authors:  Xia Kong; Sheng-Hua Wu; Li Zhang; Xiao-Qing Chen
Journal:  Exp Ther Med       Date:  2017-07-12       Impact factor: 2.447

Review 5.  Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application.

Authors:  Jan Längericht; Irene Krämer; George J Kahaly
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-14       Impact factor: 3.565

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.